DRP® Platform Expansion Beyond Small Molecules: At AACR 2025, Allarity presented a novel DRP® for daratumumab in multiple myeloma, marking the Company's first DRP developed for a targeted antibody ...

The poster will be made available on Allarity’s website later today, following 1:00 p.m. ET ... the expansion of the DRP® platform to antibody-based therapies, and the Company’s ability ...

The daratumumab DRP ® was developed by correlating gene expression patterns with sensitivity to daratumumab-induced antibody-dependent cellular cytotoxicity ... Allarity's website later today, ...

The daratumumab DRP ® was developed by correlating gene expression patterns with sensitivity to daratumumab-induced antibody-dependent ... following 1:00 p.m. ET, in the Scientific Publications ...

marking the Company’s first DRP developed for a targeted antibody therapy. This milestone expands the versatility of the DRP® platform, which was previously focused exclusively on small ...

The daratumumab DRP® was developed by correlating gene expression patterns with sensitivity to daratumumab-induced antibody-dependent cellular cytotoxicity (ADCC), based on published in vitro ...